13F Holdings
中文EN

CPHI CHINA PHARMA HOLDINGS, INC.

Pharmaceutical Preparations · NYSE · SEC CIK 1106644 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-11.0%
TTM net income YoY-22.4%
TTM EPS YoY71.6%
Revenue 3-yr CAGR-21.0%
Net income 3-yr CAGR—

Margins

Gross margin11.8%
Operating margin-111.8%
Net margin-114.3%
FCF margin—
EBITDA margin-66.2%

Returns

ROE-21.0%
ROA-15.3%
ROIC (approx.)-16.6%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets19.1%
Debt / equity0.00x
Current ratio0.26x
Interest coverage-136.51x

Cash quality & payout

Operating cash flow / net income0.04x
Accruals ratio-14.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$4.14M$4.53M$7.01M$8.10M$9.64M
Cost of revenue$4.28M$6.51M$7.29M$8.60M$9.29M
Gross profit-$131,950-$1.99M-$281,085-$493,916$349,270
R&D expense$280,901$283,942$240,080$185,858$318,964
SG&A expense$2.45M$1.78M$1.47M$1.89M$1.65M
Operating income-$3.24M-$4.59M-$2.75M-$3.55M-$2.86M
Interest expense$27,272$27,353$30,572$434,619$542,001
Pretax income-$3.19M-$4.74M-$3.08M-$3.97M-$3.40M
Net income-$3.19M-$4.74M-$3.08M-$3.97M-$3.40M
EBITDA-$1.74M-$1.97M$1,833-$848,444$227,310
EPS (basic)-0.74-2.71-0.91-3.78-0.74
EPS (diluted)-0.74-2.71-0.91-3.78-0.74
Weighted avg. shares (diluted)————46.13M
Balance sheet
Cash & equivalents$345,112$626,879$1.42M$2.03M$4.86M
Receivables$241,412$232,140$504,448$421,531—
Inventory$1.62M$2.27M$3.73M$2.95M$2.95M
Current assets$2.35M$3.27M$6.00M$5.96M$9.09M
PP&E, net$4.39M$4.88M$7.10M$9.97M$13.28M
Intangibles$24.08M$6.70M$3.26M$1.81M$147,841
Total assets$31.00M$14.89M$16.47M$17.78M$22.65M
Current liabilities$7.40M$5.02M$6.82M$12.74M$10.51M
Short-term debt$1.44M$1.14M$1.13M——
Total liabilities$8.26M$7.14M$9.01M$13.49M$16.63M
Shareholders' equity$22.74M$7.75M$7.45M$4.29M$6.02M
Shares outstanding5.52M3.26M10.63M1.50M4.73M
Cash flow statement
Operating cash flow$148,261-$406,063-$699,686-$409,545-$249,838
Capital expenditure$59,324$38,411$11,517$401,964$438,055
Free cash flow$88,937-$444,474-$711,203-$811,509-$687,893
Investing cash flow-$137,251-$291,718-$11,517-$401,964-$438,055
Financing cash flow-$294,027-$33,782$73,145-$1.77M$4.60M
Depreciation & amortization$1.50M$2.62M$2.75M$2.70M$3.09M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.